Diabetic Foot Ulcer
Conditions
Brief summary
Evaluation of the efficacy and safety of a device with LU3103209 compound versus the same device, free of LU3103209 compound, in the local management of DFUs.
Detailed description
A European prospective, randomized, double-blind, multicentre, clinical trial, conducted in three parallel groups, to evaluate the efficacy and safety of a device with LU3103209 compound versus the same device, free of LU3103209 compound, in the local management of diabetic foot ulcers (DFUs).
Interventions
DEVICEDressing with LU3103209 - Dose 1
Dressing with LU3103209 - Dose 1
DEVICEDressing with LU3103209 - Dose 2
Dressing with LU3103209 - Dose 2
DEVICEDressing without LU3103209
Dressing without LU3103209
Sponsors
Laboratoires URGO
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Male or female over 18 years old who has provided his/her written informed consent 2. Patient with Type 1 or Type 2 diabetes mellitus with glycated haemoglobin (HbA1c) level ≤ 10% 3. Inpatient or outpatient who can be monitored by the same investigating team throughout the entire study 4. Patient who agrees to wear an off-loading system during the trial 5. Diagnosis of peripheral neuropathy 6. Patient with an adequate arterial perfusion of the affected limb, confirmed by ABPI and Toe Blood Pressure assessment 7. DFU Grade 1-A or 2-A or 1-C or 2-C as defined by the University of Texas Diabetic Wound Classification System 8. Target DFU surface area between 1 cm² to 10 cm², after debridement 9. DFU present since less than 24 months
Exclusion criteria
A. Pregnant or breast-feeding woman or woman of childbearing potential not protected by an effective contraceptive method of birth control B. Patient who participated in another clinical trial in the previous month or who will take part in another clinical trial during the 12 weeks following the inclusion C. Patient with severe renal impairment D. Patient who has presented, during the 3 months before inclusion, an acute ischemic event (acute myocardial infarction or stroke) E. Patient with an active neoplastic condition, treated by radiotherapy, chemotherapy, hormone therapy or immunosuppressant F. Patient treated for a chronic disease requiring high doses of systemic corticosteroids on a daily basis (≥ 40 mg prednisolone) G. Patient with infection which is not controlled by a suitable antibiotic treatment H. Patient with any known allergy or reported adverse reaction to the trial device
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| % of Wound Area Regression (WAR), as a measure of efficacy | 12 weeks | Efficacy of dressings with LU3103209 versus dressing without LU3103209 |
Countries
Czechia, France, Italy, Poland, Spain, United Kingdom
Contacts
Primary ContactAnne Sauvadet, PhD
Backup ContactOlivier Tacca, PhD
Outcome results
None listed